Casi Pharmaceuticals Stock Price, News & Analysis
Company Description
Casi Pharmaceuticals (OTC Link: CASIF) is a publicly traded company.
CASIF stock has declined 50.2% over the past year. Shares last traded at $0.1210.
On a trailing twelve-month basis, Casi Pharmaceuticals reported revenue of $28.5M with net income of -$39.3M and diluted earnings per share of $-2.56. The company operates at a net profit margin of -137.6%.
This page provides a comprehensive overview of CASIF stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Casi Pharmaceuticals (CASIF) stock last traded at $0.1210. Over the past 12 months, the stock has lost 50.2%.
Latest News
SEC Filings
Casi Pharmaceuticals has filed 5 recent SEC filings, including 4 Form 3, 1 Form SCHEDULE 13D/A. The most recent filing was submitted on April 3, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all CASIF SEC filings →
Financial Highlights
Casi Pharmaceuticals generated $28.5M in revenue over the trailing twelve months, retaining a 39.1% gross margin, operating income reached -$39.6M (-138.8% operating margin), and net income was -$39.3M, reflecting a -137.6% net profit margin. Diluted earnings per share stood at $-2.56. The company generated -$29.2M in operating cash flow. With a current ratio of 1.09, the company maintains adequate short-term liquidity.